「no」の検索結果
164件：41～45件目を表示
-
千寿製薬株式会社
日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V m...
http://www.senju.co.jp/chinese/ -
研究开发体制 | 研究与开发 | 千寿制药株式会社
基于尖端技术与独有的研究体制，探索人与科学的无限可能性 All things in nature have a reason for being. Today’s common sense is not common sense tomorrow. 这就是我们的口号。 千寿制药通过国际性的共同研究和产学协同研究等构建了独有的研究体制，不受传统框架和固定观念的束缚，以灵活的思维迎接研究开发的挑战。着...
http://www.senju.co.jp/chinese/rd/about/ -
学会发表 | 研究与开发 | 千寿制药株式会社
le-Masked, Placebo-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Kazunori Omatsu, BSc the 59th Congress of the European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日...
http://www.senju.co.jp/chinese/rd/society/ -
发表论文 | 研究与开发 | 千寿制药株式会社
Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuki Wada2, Kazunori Omatsu2, on behalf of the SJP-0132 clinical study investigators 1: Department of Ophthalmology,...
http://www.senju.co.jp/chinese/rd/thesis/ -
Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical
lution, antibacterial ophthalmic solution, others 20202021 Overseas medical support activities were not implemented due to the impact of COVID-19. 2022 International cooperation for Vietnam antibacter...
https://www.senju.co.jp/english/about/csr01.html